Charles Homcy, Independent Director Nominee Charles Homcy, M.D. Investor Type Venture Capital. Prior to that, Dr. Homcy served as the President of Research and Development at Millennium Pharmaceuticals, Inc. (currently, Takeda Oncology), a biopharmaceutical company, following its acquisition of COR Therapeutics, Inc. in 2002.
P3 Health Partners Closes Business Combination with Whit Bernard, Senior Vice President Whit Bernard has been our Senior Vice President since September 2020. Written by P3 Health Partners Closes Business Combination with Foresight . Population Health Investment plans to leverage its management team's experience to target the healthcare therapeutics sector in the US and other developed countries. Subject to phase-in rules and a limited exception, the rules of Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. The search included articles indexed in PubMed using subject headings with (MeSH . Renaissance Capital->. P3 believes its extensive experience managing Medicare Advantage populations drives its model, which simultaneously improves care and decreases costs. The health population management company said the deal is expected to provide it with cash proceeds of at least $180 million and includes more than $200 million in private investment from. Read more. Access them all or just read their earnings: https://last10k.com/sec-filings/phic/0001193125-22-150758.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=phic, $PHIC Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC All rights reserved. An investment company focused on innovative therapeutics with the potential to transform health outcomes for populations We , https://www.linkedin.com/company/populationhp, Health (4 days ago) Cadwalader is advising Population Health Investment Co., Inc. (Nasdaq: PHICU) on its $150 million initial public offering of 15,000,000 units at a price of $10.00 per unit. See who we are. Ms. Champsis qualifications to serve on our Board of Directors include her significant business and finance experience in the biotech industry. Chris Visioli, Chief Financial Officer Chris Visioli has been our Chief Financial Officer since September 2020. and an M.D. P3 Health Partners was a portfolio company of Chicago Pacific Founders, which is exiting its investment in the company. Population Health Investment, a blank check company targeting a therapeutics business, raised $150 million by offering 15 million units at $10. Prior to December 2018, he served as The Medicine Companys chief executive officer since February 2012, The Medicine Companys chief executive officer and president from October 2009 to February 2012, The Medicine Companys chief executive officer from August 2004 to October 2009, as The Medicine Companys president from August 2004 to December 2004, The Medicine Companys executive chairman from September 2001 to August 2004 and The Medicine Companys chief executive officer and president from 1996 to September 2001. Ordinary Share files form 10-Q https://fintel.io/sf/us/phic?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing, Population Health Investment Co., Inc. Just Filed Its Quarterly Report: Net Income (Loss) Pe https://www.conferencecalltranscripts.com/summary/?id=11184250 $PHIC, $PHIC just filed a 10-Q Quarterly Report with 5 financial statements and 28 disclosures. The transaction was approved at a meeting of Foresight's stockholders Dec. 3. Population health partners spac Population health continuing education Public health improvement partners.
P3 Health Partners to go public via $2.3 billion SPAC merger At the proposed deal size, Population Health Investment would command a market value of $188 million. The SPAC will concentrate on the real estate, healthcare and technology sectors, especially companies engaged in digitalization of property . The audit committee is responsible for: meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; monitoring the independence of the independent registered public accounting firm; verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; inquiring and discussing with management our, https://www.sec.gov/Archives/edgar/data/1825724/000119312522220046/d697660d10q.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312522150758/d311529d10q.htm, https://www.sec.gov/Archives/edgar/data/1825724/000127308722000068/PHIC_SC13G.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312522089828/d296030d10k.htm, https://www.sec.gov/Archives/edgar/data/1825724/000135482122000004/phic022022.txt, https://www.sec.gov/Archives/edgar/data/1825724/000119312522042023/d257772dsc13ga.htm, https://www.sec.gov/Archives/edgar/data/1825724/000107680922000082/phicu20211231.htm, https://www.sec.gov/Archives/edgar/data/1825724/000110465922020364/tm225968d3_sc13ga.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312522025794/d274531dsc13g.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312522004571/d255093d10qa.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312522004568/d229009d10ka.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312521364981/d267895d8k.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312521327614/d245915d10q.htm, https://www.sec.gov/Archives/edgar/data/1825724/000089924321034190/xslF345X03/doc4.xml, https://www.sec.gov/Archives/edgar/data/1825724/000119312521246065/d156200d10q.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312521171058/d159482d10q.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312521166732/d12374d10ka.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312521163139/d528894dnt10q.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312521159781/d868054d8k.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312521102107/d34654d10k.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312521044449/d133365dsc13g.htm, https://www.sec.gov/Archives/edgar/data/1825724/000107680921000105/phicu20201231.htm, https://www.sec.gov/Archives/edgar/data/1825724/000089924321003646/xslF345X03/doc4.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924321003406/xslF345X03/doc4.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924321003404/xslF345X03/doc4.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924321003403/xslF345X03/doc4.xml, https://www.sec.gov/Archives/edgar/data/1825724/000119312521002016/d26659d8k.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312520304560/d47340d8k.htm, https://www.sec.gov/Archives/edgar/data/1825724/000110465920129200/tm2037051-2_sc13g.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312520299501/d71062d8k.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312520298125/d48600d424b4.htm, https://www.sec.gov/Archives/edgar/data/1825724/999999999520003207/xslEFFECTX01/primary_doc.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031358/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031357/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031356/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031354/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031352/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031351/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031347/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031346/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000089924320031344/xslF345X02/doc3.xml, https://www.sec.gov/Archives/edgar/data/1825724/000135445720000695/8A_Cert_PHIC.pdf, https://www.sec.gov/Archives/edgar/data/1825724/000119312520294075/d28960d8a12b.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312520290958/d48600ds1a.htm, https://www.sec.gov/Archives/edgar/data/1825724/000119312520282558/d48600ds1.htm, https://www.sec.gov/Archives/edgar/data/1825724/000095012320009913/filename1.htm, First Tr Exchange Traded Fd-First Trust Merger Arbitrage Fd, Blackstone Alternative Multi-Strategy Fund. 125 Table of Contents Previously, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. https://newsfilter.io/a/952b58812bbd299bd76e86eb330e2bf4, Our officers, directors and director nominees are as follows: Name Age Position Clive Meanwell 63 Chief Executive Officer; Director Ian Read 67 Executive Chairman; Director Nominee Christopher Visioli 44 Chief Financial Officer Chris Cox 55 Senior Vice President Whit Bernard 36 Senior Vice President Farah Champsi 59 Director Nominee Clarke Futch 53 Director Nominee Charles Homcy 70 Director Nominee Our founding team Clive Meanwell, Co-Founder; Chief Executive Officer; Director Clive Meanwell is our co-founder and has been our Chief Executive Officer since September 2020. These membership benefits include: Were here to simplify healthcare, advocate for , Health (6 days ago) Founders Clive Meanwell. We believe the Company will benefit from Ms. Champsis extensive network and reputation for constructive, active engagement and trusted working relationships with managements of dynamic, fast-growth companies. Methods: The review was primarily driven by a search of the literature from July 1, 2016 to September 30, 2017. Population Health Investment, a blank check company targeting a therapeutics business, filed on Friday with the SEC to raise up to , https://www.nasdaq.com/articles/therapeutics-spac-population-health-investment-files-for-a-%24150-million-ipo-2020-10-30, Health (3 days ago) Therapeutics SPAC Population Health Investment files for Health (Just Now) Published.
Dr. Meanwell received an M.D.
P3 Health Partners - We support healthier patients and communities. December 03, 2021 17:24 ET | Source: P3 Health Group LLC. Population Health Investment, a blank check company targeting a , https://www.health-improve.org/population-health-partners-spac/, Health (2 days ago) October 30, 2020. The term of office of the third class of directors, consisting of , will expire at our third annual general meeting. The article Therapeutics SPAC Population Health Investment files for a $150 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. He currently serves on the board of directors of Portola Pharmaceuticals, 127 Table of Contents Inc. (Nasdaq: PTLA), a position he has held since 2004, and of Global Blood Therapeutics, Inc. (Nasdaq: GBT). Population Health Investment, which is targeting therapeutics companies, plans to start trading today on the Nasdaq under PHICU. Get your FREE TRIAL now. The charter of each committee will be available on our website. from the University of Missouri.
Type a symbol or company name. Showing 1-50 of 99 . Bernard is currently a Founding Partner at Population Health Partners. Each committee will operate under a charter that has been approved by our board of directors and will have the composition and responsibilities described below.
Top 10 Companies In Population Health Management Solutions Market https://www.bing.com/aclk?ld=e8u9JJW2aSRivvn0PDPbzZCzVUCUwRHSswfqmkBKIcGSb3KdKWCZB1xCkroJGN6Jevtaserdkyzcb7DycyUMIef4BdTKf47srbaIKyBzu-I_L00X1xzHbM6oGYygGMaZ0_AfRwJ5sl1WubQjGIGUbEpVNitNXQZ_LZCRnjogXPq5HCXZhFLf-uZrfNx996dHet36W10Q&u=aHR0cHMlM2ElMmYlMmZyaW1pZGkuY29tJTJmcG9wdWxhdGlvbi1oZWFsdGgtbWFuYWdlbWVudCUzZnV0bV9zb3VyY2UlM2RiaW5nJTI2dXRtX21lZGl1bSUzZGNwYyUyNnV0bV9jYW1wYWlnbiUzZHBobSUyNm1zY2xraWQlM2RlOTlhOTFmZWVkYzQxNWI5NTI5ZWYyOTIwYjU2MjU3ZQ&rlid=e99a91feedc415b9529ef2920b56257e, Health (9 days ago) Better healthcare. Access them all or just read their earnings: https://last10k.com/sec-filings/phic/0001193125-22-220046.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=phic, $PHIC Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC Subject to phase-in rules and a limited exception, the rules of Nasdaq require that the compensation committee of a listed company be comprised solely of independent directors. SPAC Target Ticker Status Sector; Foresight Acquisition Corp. P3 Health Partners: FORE: Deal Closed: Healthcare .
P3 Health Partners Merging with Foresight - DealFlow's SPAC News Prior to joining The Medicine Company and before going to business school, Mr. Visioli was a management consultant for Ernst & Young LLP. The New York, NY-based company plans to raise $150 million by offering 15 million units at a price of $10.
Anji Pharma and Population Health Partners Enter into Strategic Population Health Management Solutions Market is expected to reach USD 58.11 billion by 2023 from USD 19.79 billion in 2018, at a CAGR of 24.0% during the forecast period (2018-2023). Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Director independence The rules of Nasdaq require that a majority of our board of directors be independent. Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our founder shares.
Therapeutics SPAC Population Health Investment prices $150 million IPO Mr. Read was Chairman and Chief Executive Officer of Pfizer from December 2010 until January 2019, and Executive Chairman until December 2019. Seeking Target. . Read More Science 37 Goes Public in SPAC Deal Our board of directors has determined that each of are independent. This SPAC - Special Purpose Acquisition Corporation- is intended to acquire health companies of all kinds, with the restriction that they have to supply natural products and use non invasive and environment friendly techniques. from Smith College and an M.B.A. from Stanford University. He is also a Senior Counsel at Cadwalader, Wickersham & Taft LLP, which he joined as a partner in January 2012. Dun & Bradstreet gathers Health Care and Social Assistance business information from trusted sources to help you understand company performance, growth potential, and competitive pressures. All of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed business combination. Oct 30, 2020 07:27PM EDT. The company is led byCEO and Director Clive Meanwell, who is a Founding Partner of Population Health Partners and founded The Medicines Company in 1996. has served as a director of BridgeBio since November 2018, Chairman of Pharmaceuticals since February 2019, and Lead Director since February 2020. Each member of the audit committee meets the financial literacy requirements of Nasdaq and our board of directors has determined that qualifies as an audit committee financial expert as defined in applicable SEC rules and has accounting or related financial management expertise. He led many efforts in the organization to acquire products and establish partnerships in addition to leading long-term strategy and financial planning work. Explore our IPO Center to track upcoming deals, analyze performance and read IPO news and expert commentary. Over 40% of Population Health members have had one or more emergency room visits in the last year, while almost 20% have had two or more visits in the past year. Health (4 days ago) Population Health Investment, a blank check company targeting a therapeutics business, raised $150 million by offering 15 million units at $10.
Population Health Investment $172.5 million IPO | Davis Polk Nauen (Brandenburg, Census Population, Germany) - Population Statistics P3 Health Partners is a patient-centered and physician-led population health management company that supports providers, physicians and practices as they.
Population Health Partners Llc - Health Improve SNFs & other PAC providers are working with countless other payers/providers. NAICS CODES: 62. Prior to joining McKinsey, Mr. Bernard worked in the arts, as a Fulbright Scholar in Latvia and then Director of Development at the International Contemporary Ensemble. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our founding teams motivation in identifying or selecting a partner business but we do not believe that the ability of our founding team to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. Worldwide Commercial UAS Industry - Key Drivers, Restraints, Trends and Significant Growth Opportunities, Population Health Investment Co Inc (PHIC) CEO Clive Meanwell Bought $160,720 of Shares, $PHIC hit 52 week high (Ord Cl A/Population Health Investment Co Inc) https://www.dividendinvestor.com/dividend-news/?symbol=phic, $PHIC BUY/SELL METER Alert Cross 31% +- Technical Analysis https://t8sk.com/PHIC, $PHIC / Population Health Investment Co., Inc. Population Health Investment, a blank check company targeting a therapeutics business, filed on Friday with the SEC to raise up to $150 million in an initial public offering. pipeline, calendar, enhanced profiles, data screens, valuation metrics, and more. Published: 2015/01/06 Preview / Show more . Get premium features like the IPO
Population Health Prices $150M IPO | DealFlow's SPAC News A Population Health membership can connect you to prescription drug savings and management, meal delivery programs, free rides to doctor's appointments, primary care coordination, mental health and wellness programs, hearing services and more. (2 days ago) Population Health Improvement Partners is a nonprofit organization passionate about working with your team to tackle your change challenges and foster successful outcomes. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Dr. Meanwell is a Founding Partner of Population Health Partners.
P3 Health Partners Inc. - PIII SPAC - spacHero.com He is joined by Executive Chairman Ian Read, who previously served as CEO of Pfizer from 2010 to 2019, and CFO Chris Visioli, the former CFO of The Medicines Company. IPO Pro
The New York, NY-based company plans to raise $150 million by offering 15 million units at a price of $10. An independent director is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship with the company which in the opinion of the companys board of directors, could interfere with the directors exercise of independent judgment in carrying out the responsibilities of a director. to know about the IPO market in one platform. to know about the IPO market in one platform. Chris Cox, Senior Vice President Chris Cox has been our Senior Vice President since September 2020. Clarke Futch, Independent Director Nominee Clarke Futch brings over 30 years of experience in biopharmaceutical/healthcare investing and financing, having raised over $5 billion across eight investment vehicles, and executed more than 100 transactions, including royalty, equity, debt and M&A deals. 1 minute read. will serve as the chairman of the audit committee. and gain actionable insights into the global IPO market with pre-IPO reports and models. The gold standard for independent pre-IPO research. She currently serves on the board of UCSF Benioff Childrens Hospitals and as a trustee of Smith College. The company is led by CEO Clive Meanwell, who is a Founding Partner of Population Health Partners and founded The Medicines Company in 1996. As the discussion about how to modify the social determinants of population health at the community level continues, it is clear that the field needs to have clear .
Population Health Partners Developing Community Partners For Population Health Management Objective: To summarize the recent public and population health informatics literature with a focus on the synergistic "bridging" of electronic data to benefit communities and other populations. and gain actionable insights into the global IPO market with pre-IPO reports and models. J.P. Morgan acted as a lead manager on the deal.
PHIC SPAC Population Health Investment Co., Inc. - SPAC Our independent directors will have regularly scheduled meetings at which only independent directors are present. In addition, prior to the completion of an initial business combination, holders of a majority of our founder shares may remove a member of the board of directors for any reason. Mr. Visioli received an M.B.A. with Honors, from Columbia Business School and a B.S. Population Health Investment filed confidentially on September 24, 2020. Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50. From December, 2018 to April, 2020, Mr. Bernard was the Senior Vice President of Commercial Strategy and Business Development for The Medicines Company, which was acquired by Novartis in for $9.7 billion in January 2020. The company is led by CEO and Director Clive Meanwell, who is a Founding Partner of Population Health Partners and founded The Medicines Company in 1996. We do not intend to take any action to ensure that members of our founding team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. Don't risk buying another IPO without IPO Pro. (M.B. Industry: Medical Care Facilities. Get started by calling 1-855-445-1331. Each unit will consist of one share of common stock and 1/3 of a warrant, exercisable at $11.50. Executive officer and director compensation None of our executive officers or directors have received any cash compensation for services rendered to us. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
P3 Health Partners Spac Ms. Champsi received a B.A. Important Disclosures
Connect You to Free Benefits Population Health Investment Co., Inc. is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Population Health Partners Health (5 days ago) Population Health Partners is a new type of firm bridging venture capital and private equity, committed to building great companies and generating superior returns for our investing partners by solving the health and economic challenges presented by prevalent diseases. Population health partners spac. The , https://www.cadwalader.com/news/news-release/cadwalader-advises-population-health-investment-co-on-150-million-ipo, Health (7 days ago) December 6, 2021. Partnership Founded 2020 Employees at Population Health Partners Richard Fires, MBA, GPHR Entrepreneural Human Strategist Greg Williams C-Level Biotech & Pharmaceutical Executive | CEO & Board. Population Health Investment intends to capitalize on the experience of its founders and management in order to target the healthcare therapeutics sector in the United States and other developed countries.
P3 Health Partners Closes Business Combination - DealFlow's SPAC News Farah Champsi, Independent Director Nominee Farah Champsi has spent over 30 years evaluating, advising and building companies in the life sciences industry as a Managing Director at Alta Partners, a leading venture capital firm and as a senior banker at Robertson 126 Table of Contents Stephens, a preeminent emerging growth investment bank.
Book a meeting room in Berlin - Brandenburg - Nauen instantly | Catering and meeting equipment | 4000 spaces worldwide | Customer support
Population Health Improvement Partners Population Health Investment plans to list on the Nasdaq under the symbol PHICU. PACs don't have the resources to execute your population health strategy. P3 Health Partners, a population health management company, closed its business combination with blank-check company Foresight , https://news.spacconference.com/2021/12/06/p3-health-partners-closes-business-combination-with-foresight-acquisition/, Health (1 days ago) Description: P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United , Health (5 days ago) Population Health is a free membership service that can connect you to healthcare benefits in your area. He is joined by Executive Chairman Ian Read , who previously served as CEO of Pfizer from 2010 to 2019, and CFO Chris Visioli , the former CFO of The Medicines Company. NEW YORK, Dec. 03, 2021 (GLOBE NEWSWIRE) -- P3 Health Partners ("P3" or "Company"), a patient-centered and physician-led . When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Our amended and restated memorandum and articles of association provides that our officers may consist of one or more chairman of the board, chief executive officer, chief financial officer, chief business officer, president, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. Population Health Investment, a blank check company targeting a therapeutics business, filed on Friday with the SEC to raise up to $150 million in an initial public offering. He is joined byExecutive Chairman Ian Read, who previously served as CEO of Pfizer from 2010 to 2019, andCFO Chris Visioli, the former CFO of The Medicines Company. Health SPAC. He also serves as Chairman of DXC Technology and will become a founding member of the Board of Directors of Viatris upon the completion of that companys formation. Renaissance Capital LLC is an SEC-registered investment adviser. Therapeutics SPAC Population Health Investment files for a $150 million IPO, Renaissance International ETF (symbol: IPOS), Do Not Sell My Personal Information (CA Residents Only). Listing Websites about Population Health Improvement Partners.
Foresight Acquisition / P3 Health Partners - SPAC Alpha Dr. Meanwells qualifications to serve on our Board of Directors include his significant experience building and leading successful biotechnology companies, developing pharmaceuticals and his scientific expertise.
Nauen (Havelland, Brandenburg, Germany) - Population Statistics, Charts Prior to January 2012, he was a partner at Cahill Gordon & Reindel. from Brown University and an M.B.A. from the Kellogg School of Management at Northwestern University. Population Health focuses on increasing member's health care literacy by supporting appropriate navigation of healthcare services to empower members to utilize the right site of care .